3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
7
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
307
Recurrence
64
Neoplasms
32
Neoplasms, Plasma Cell
17
Lymphoma, Non-Hodgkin
14
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Vomiting
11
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Nausea
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Ovarian Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Hematologic Neoplasms
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Paraproteinemias
5
Lung Neoplasms
5
Leukemia
5
Small Cell Lung Carcinoma
4
Renal Insufficiency
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Plasmacytoma
4
Lymphoma, Follicular
4
Hematologic Diseases
4
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Breast Neoplasms
3
Interventions
nilotinib
4
Imatinib Mesylate
4
Dasatinib
4
troxacitabine
1
ponatinib
1
litronesib
1
exatecan
1
carfilzomib
1
bosutinib
1
blinatumomab
1
asciminib
1
TAK-901
1
STA 9090
1
Panobinostat
1
Homoharringtonine
1
Fentanyl
1
Dexamethasone
1
Decitabine
1
Calcium Dobesilate
1
2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Blast Crisis
×
Dexamethasone
×
Clear all
NCT01204164
2016-05-06
TG02-101
Tragara Pharmaceuticals, Inc.
Phase 1
Completed
120 enrolled